U.S., June 16 -- ClinicalTrials.gov registry received information related to the study (NCT07648745) titled 'Does Cediranib Prevent Bowel Perforation in Platinum-resistant Ovarian Cancer' on Oct. 11, 2018.
Brief Summary: Ovarian cancer can often grow and cause obstructions in the bowel. These obstructions usually cannot be removed with surgery and can be fatal. This trial is testing whether a drug called cediranib can be used safely together with paclitaxel chemotherapy to treat ovarian cancer in women at risk of bowel obstructions. All participants will receive the cediranib/paclitaxel combination, and if the cancer worsens the participant will stop receiving paclitaxel and may receive an additional drug, olaparib, together with cediranib...